Clay B. Siegall - 05 May 2022 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Reporting relationship: Director
Issuer ticker: NRIX
Reported as of: 05 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 May 2022, 17:43:06 UTC
Prior SEC filing: 22 Apr 2022
Next SEC filing: 13 May 2022
Source filing: View source filing
Reporting owner signature: /s/ Christine Ring, as Attorney-in-Fact for Clay B. Siegall

Key filing fact

Clay B. Siegall filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 06 May 2022.

Key facts

This page summarizes Clay B. Siegall's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 May 2022, 17:43.

Change

Previous filing in this sequence was filed on 22 Apr 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value: $0
Shares: +17,500
Change %
Price: $0.000000
Shares after: 17,500
Date: 05 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $10.39
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 5, 2023, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.